Table 1.
A summary of the current ongoing Phase III and Phase IV trials
| Drug | Phase | Indication |
|---|---|---|
| CIK (cytokine-induced killer cells) Temozolomide |
IV | Advanced malignant gliomas |
| Bevacizumab Temozolomide |
III | Recurrent GBM |
| VAL-083 (dianhydrogalacticol) Temozolomide or lomustine or carboplatin |
III | GBM |
| Nivolumab Bevacizumab Ipilimumab |
III | Recurrent GBM |
| VB-111 Bevacizumab |
III | GBM |
| Alpha-IFN Temozolomide |
III | Glioblastoma |
| Toca 511 Toca FC Lomustine Temozolomide Bevacizumab |
II/III | GBM |
Abbreviation: GBM, glioblastoma multiforme.